Triggered doxorubicin release using redox-sensitive hyaluronic acid-g-stearic acid micelles for targeted cancer therapy☆

Add time:08/29/2019    Source:sciencedirect.com

To develop a carrier for targeted drug delivery and triggered drug release in a reducing-tumor environment, reduction-sensitive hyaluronic acid-g-stearic acid (HCS) micelles were synthesized using a coupling agent. The HCS 40% was shown to have a more compact particle size than HCS 20% and the particle size of doxorubicin (DOX)-loaded HCS (HCSD) was increased relative to that of HCS micelles. The behavior of DOX release from HCSD showed that DOX was rapidly released in GSH (10 mM) solution. The site-specific targeting effect of HCSD nanoparticles was investigated by cellular uptake and competition assay at HCT116 and CT26 cell lines. An in vivo study of HCSD revealed that tumor suppression and site-specific targeted delivery of HCSD nanoparticles in HCT116-xenografted tumors were more superb than in the CT26-xenografted tumor. These results suggest that HCSD nanoparticles can be expected to have high therapeutic efficacy because they enable targeted drug delivery and rapid drug release.

We also recommend Trading Suppliers and Manufacturers of 4-(5-Ethyl-2-thiazolyl)-α-methylbenzeneacetic acid (cas 138568-67-9). Pls Click Website Link as below: cas 138568-67-9 suppliers

Prev:Biomimetic Polypeptoids with para-Oligo(ethylene glycol) Benzyl Side-chains Synthesized from α-Amino Acids
Next:Synthesis and antimicrobial activities of new higher amino acid Schiff base derivatives of 6-aminopenicillanic acid and 7-aminocephalosporanic acid)